Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
CancerHLA-A*02:01-positive
Interventions
DRUG

IMC-R117C

IV infusion

DRUG

Chemotherapy drug

IV infusion

DRUG

Chemotherapy drug

oral

DRUG

Kinase inhibitor

oral

DRUG

Antiangiogenic Agent

IV infusion

DRUG

Monoclonal antibody

IV infusion

Trial Locations (12)

1070

RECRUITING

Institut Jules Bordet, Anderlecht

3000

RECRUITING

UZ Leuven, Leuven

20089

RECRUITING

nstituto Clinico Humanitas, Rozzano

Unknown

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

RECRUITING

Universitair Ziekenhuis Gent, Ghent

RECRUITING

Universitaetsklinikum Heidelberg, Heidelberg

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

RECRUITING

Hospital HM Nou Delfos, Barcelona

RECRUITING

VHIO, Vall d'Hebron University Hospital, Barcelona

RECRUITING

Centro Integral Oncologico Clara Campal, Madrid

RECRUITING

Hospital Universitario Fundacion Jimenez Diaz, Madrid

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Immunocore Ltd

INDUSTRY